The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Shingrix, GSK’s shingles vaccine, saw a modest 1% increase in sales, while sales for its respiratory syncytial virus (RSV) vaccine Arexvy dropped by 51%. CEO Emma Walmsley acknowledged the ...

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

His roles included serving as Senior Vice President, Vaccine Research and Development, for Pfizer Inc ... and Head of Global Adjuvant Centre for Vaccine Development at GSK Biologicals.

Even as GSK’s RSV vaccine launch hits a serious slowdown ... Miels explained. On Tuesday, Pfizer also reported $198 million in fourth-quarter sales for its RSV shot Abrysvo.

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both companies ...

Overall vaccine sales declined by 4% in 2024. Shingrix, GSK’s shingles vaccine, saw a modest 1% increase in sales, while sales for its respiratory syncytial virus (RSV) vaccine Arexvy dropped by 51%.

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees ... heavy-hitting competition. GSK’s Arexvy has been leading the charge in the RSV vaccine sales race so far.

Kennedy's promises on vaccines secure senior Republican senator's vote February 4, 2025 Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it ...